Navigation Links
Pharmacyclics Announces Presentations on Its Novel and Selective,HDAC and Bruton's Tyrosine Kinase Inhibitor Compounds

mas, and is active in an animal arthritis model Abstract #5398: 8:00 a.m. -12:00 p.m. Presenter: Lee Honigberg, Ph.D., Pharmacyclics, Inc. Session: Miscellaneous Anticancer Agents Poster Presentation: Synthesis and anticancer properties of water-soluble zinc ionophores Abstract #5606: 8:00 a.m. -12:00 p.m. Presenter: Darren Magda, Ph.D., Pharmacyclics, Inc.

Pharmacyclics is a pharmaceutical company developing innovative products to treat cancer and other serious diseases. The company is leveraging its small-molecule drug development expertise to build a pipeline in oncology and other diseases based on a wide range of targets, pathways and mechanisms. Its lead product, Xcytrin(R) (motexafin gadolinium) Injection, has completed Phase 3 clinical trials and several ongoing Phase 1 and Phase 2 clinical trials are evaluating Xcytrin as a single agent or in combination with chemotherapy and/or radiation in multiple cancer types. More information about the company, its technology, and products can be found at www.pharmacyclics.com . Pharmacyclics(R), Xcytrin(R) and the "pentadentate" logo(R) are registered trademarks of Pharmacyclics, Inc.

NOTE: Other than statements of historical fact, the statements made in this press release about plans for our NDA filing, enrollment and future plans for our clinical trials, progress of and reports of results from preclinical and clinical studies, clinical development plans and product development activities are forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. The words "believe," "will," "may," "continue," "plan," "expect," "intend," "anticipate," variations of such words, and similar expressions also identify forward-looking statements, but their absence does not mean that the statement is not forward-looking. The forwar
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Pharmacyclics Announces Interim Results From Two Ongoing Phase 2 Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat Recurrent Non-Small Cell Lung Cancer
2. Pharmacyclics Announces Promising Results From Phase 2 Clinical Trial of Xcytrin in Recurrent, Metastatic Non-Small Cell Lung Cancer
3. Pharmacyclics Announces Presentations and Published Abstracts on Xcytrin at The 2007 American Society of Clinical Oncology Annual Meeting
4. Pharmacyclics Identifies Functional Biomarkers for its Novel HDAC Inhibitor and Demonstrates Preclinical Anti-Tumor Activity with Brutons Tyrosine Kinase Inhibitors
5. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
(Date:12/17/2014)... 17, 2014 , ... a hub of information concerning the biopharmaceutical Group,s national and ... further addition to the recently launched institutional website that is ... been enriched by a new chapter in the fascinating story ... richly detailed and panoramic hub on the world of clinical ...
(Date:12/17/2014)... 17, 2014  IGI Laboratories, Inc. (NYSE MKT: IG; ... its offering of $125 million aggregate principal amount of ... Notes were offered and sold only to qualified institutional ... of 1933, as amended (the "Securities Act"). ... 3.75% per year, payable semiannually in arrears on June ...
(Date:12/17/2014)... and RALEIGH, N.C. , ... Communications, LLC (CTMC), and Integrated Clinical Trial Services, ... and retention for clinical trials announce that they ... Trial Marketing Services (i-CTMS). i-CTMS will provide a ... to pharmaceutical, biotechnology and medical device companies. ...
Breaking Medicine Technology:Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 2Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 3IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 2IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 3IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 4Integrated Clinical Trial Services and Clinical Trial Marketing Communications Form Joint Venture 2Integrated Clinical Trial Services and Clinical Trial Marketing Communications Form Joint Venture 3
... PARSIPPANY, N.J., Nov. 30, 2011  Watson Pharmaceuticals, Inc. (NYSE: ... Inc., has launched an authorized generic version of LIPITOR® ... exclusive agreement with Pfizer Inc.  Watson began shipping the ... adjunct to diet to reduce elevated total cholesterol, LDL, ...
... 2011  Vantage Health (OTC:BB – ticker symbol VNTH), ("Company"), ... Health Tanzania Limited ("VHTL"), was awarded Lot 1, Lot ... es Salaam ("University") pharmaceutical and medical supply tender number ... value for lot 1, lot 2 and lot 3 ...
Cached Medicine Technology:Watson Launches Generic LIPITOR® 2Watson Launches Generic LIPITOR® 3Vantage Health 51% Owned Tanzanian Subsidiary Awarded Lot 1, Lot 2 and Lot 3 of University of Dar Es Salaam Pharmaceutical and Medical Supply Tender 2Vantage Health 51% Owned Tanzanian Subsidiary Awarded Lot 1, Lot 2 and Lot 3 of University of Dar Es Salaam Pharmaceutical and Medical Supply Tender 3
(Date:12/19/2014)... Santa Rosa, CA (PRWEB) December 19, 2014 ... 2x4 and 5x5 SuperClone Rooms. SuperCloset continues to offer ... grow solutions. Pair one of the new SuperClone Rooms ... truly professional, perpetual, and turnkey indoor hydroponic grow room ... cloner in the world, SuperCloset’s SuperPonic SuperCloner 50 ...
(Date:12/19/2014)... The Medspa at Hendrick in Abilene, TX presents ... brand Juvéderm. Voluma XC treats volume loss in cheeks, ... Hendrick is pleased to be able to offer this ... clients. , Voluma is the first and only injectable ... mid-face and cheek area. This non-invasive treatment targets volume ...
(Date:12/19/2014)... FRIDAY, Dec. 19, 2014 (HealthDay News) -- All children ... 3 and 6, preferably every year, eye experts say. ... from an expert panel of the U.S. National Center ... children in this age group require screening for eye ... glasses, such as amblyopia ("lazy eye") and strabismus (a ...
(Date:12/19/2014)... Dec. 19, 2014 (HealthDay News) -- The cost of ... well-being, a new study finds. Researchers examined data ... been diagnosed with colorectal or lung cancer. Of those ... cancer-free, and more than 100 had advanced cancer. ... to pay their medical bills, which was linked with ...
(Date:12/19/2014)... Dennis Thompson HealthDay Reporter ... Ebola,s entrance into the United States -- along with ... outbreak -- have highlighted cracks in the nation,s public ... health policy report released Thursday. Half of U.S. ... to infectious disease outbreaks. That was the main conclusion ...
Breaking Medicine News(10 mins):Health News:SuperCloset Continues to Innovate with New Complete Indoor Grow Room Packages, The SuperClone Rooms are the Newest Addition to the Award Winning SuperRoom Lineup 2Health News:Breakthrough New Injectable Dermal Filler Voluma XC Offered by The MedSpa at Hendrick 2Health News:Preschoolers Need Eye Screening, Experts Say 2Health News:Cancer Treatment Costs Weigh Heavily on Patients, Study Finds 2Health News:Most States Not Ready to Handle Infectious Disease Outbreaks: Report 2Health News:Most States Not Ready to Handle Infectious Disease Outbreaks: Report 3Health News:Most States Not Ready to Handle Infectious Disease Outbreaks: Report 4
... Blue companies, stewardship of,healthcare dollars, WASHINGTON, June ... investigations resulted in overall savings and,recoveries of more ... released,by the Blue Cross and Blue Shield Association ... Blue Cross and Blue Shield companies, anti-fraud,units was ...
... HARRISBURG, Pa., June 19 Four illnesses,caused ... State Health Secretary Dr. Calvin B. Johnson announced ... Salmonella outbreak,associated with tomatoes that has produced at ... has been identified in Bucks, Butler, Lancaster, and,Warren ...
... year, the ESMO International Symposium: 10th World ... from 6 leading professional societies and organizations, ... the premier platform for specialists in cancer ... review the state-of-the-art in gastrointestinal cancer and ...
... the Necessity of ... Healthcare ... to gauge,healthcare professionals, attitudes about universal coverage and the,candidates, programs, ... the U.S. A nationwide,representative sample of 336 general practitioners, internal ...
... - Adds $47 million in annual revenues and eight locations in ... Connecticut, ... Inc.,(Nasdaq: AFAM ), a leading regional provider of home health ... the stock of Patient Care, Inc. This acquisition, the Company,s,largest to ...
... Schmidt teams up with Minor League Baseball(TM) to raise awareness of, ... ... in the U.S., BRIDGEWATER, N.J., June 19 Hall of Fame ... teamed up to launch BPH Game Plan Starts with U:,Catch the Whole ...
Cached Medicine News:Health News:Blue Cross and Blue Shield Companies' Anti-Fraud Units Recover and Save More Than $249 Million In 2007 2Health News:Blue Cross and Blue Shield Companies' Anti-Fraud Units Recover and Save More Than $249 Million In 2007 3Health News:Pennsylvania Department of Health Investigates Salmonella Cases Linked to National Outbreak 2Health News:10th World Congress on Gastrointestinal Cancer -- Barcelona, Spain 2Health News:U.S. Healthcare Professionals Speak Out on Universal Healthcare and the Presidential Candidates' Platforms 2Health News:U.S. Healthcare Professionals Speak Out on Universal Healthcare and the Presidential Candidates' Platforms 3Health News:U.S. Healthcare Professionals Speak Out on Universal Healthcare and the Presidential Candidates' Platforms 4Health News:U.S. Healthcare Professionals Speak Out on Universal Healthcare and the Presidential Candidates' Platforms 5Health News:Almost Family, Inc. Signs Definitive Agreement to Acquire Patient Care, Inc. 2Health News:Almost Family, Inc. Signs Definitive Agreement to Acquire Patient Care, Inc. 3Health News:Almost Family, Inc. Signs Definitive Agreement to Acquire Patient Care, Inc. 4Health News:Hall of Fame Baseball Legend Mike Schmidt Speaks Out for the First Time About Common Health Problem in Older Men 2Health News:Hall of Fame Baseball Legend Mike Schmidt Speaks Out for the First Time About Common Health Problem in Older Men 3Health News:Hall of Fame Baseball Legend Mike Schmidt Speaks Out for the First Time About Common Health Problem in Older Men 4Health News:Hall of Fame Baseball Legend Mike Schmidt Speaks Out for the First Time About Common Health Problem in Older Men 5
Provides access via PDA to determine whether imaging examinations are necessary based on symptons and which studies will generate the most information....
PDA-version of the standard reference work in rheumatology....
PDA version of the best-selling guide....
More than 200 key diagnostic and treatment tables culled from Tierney's Current Medical Diagnostics and Treatment 2003....
Medicine Products: